Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petermolo A, Zafeiriou Z, Fontes M, Perez-Lopez R, Tunariu N, Fulton B, Jones R, McGovern U, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Mateo J, et al. Among authors: rescigno p. J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031. J Clin Invest. 2020. PMID: 31874108 Free PMC article. Clinical Trial.
Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, Maruzzo M, Giannarelli D, Tortora G, Galli L, Rizzo M, De Giorgi U, Antonuzzo L, Bracarda S, Cartenì G, Atzori F, Tamberi S, Procopio G, Fratino L, Lo Re G, Santoni M, Baldessari C, Astone A, Calabrò F, Brunelli M, Porta C, Rescigno P, Basso U, Fornarini G. Rebuzzi SE, et al. Among authors: rescigno p. ESMO Open. 2022 Dec;7(6):100634. doi: 10.1016/j.esmoop.2022.100634. Epub 2022 Dec 6. ESMO Open. 2022. PMID: 36493602 Free PMC article.
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study.
Rebuzzi SE, Brunelli M, Galuppini F, Vellone VG, Signori A, Catalano F, Damassi A, Gaggero G, Rescigno P, Maruzzo M, Merler S, Vignani F, Cavo A, Basso U, Milella M, Panepinto O, Mencoboni M, Sbaraglia M, Dei Tos AP, Murianni V, Cremante M, Llaja Obispo MA, Maffezzoli M, Banna GL, Buti S, Fornarini G. Rebuzzi SE, et al. Among authors: rescigno p. Cancers (Basel). 2023 Apr 21;15(8):2394. doi: 10.3390/cancers15082394. Cancers (Basel). 2023. PMID: 37190322 Free PMC article.
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
Fornarini G, Rebuzzi SE, Buti S, Rescigno P, Merseburger A, Sternberg CN, de Giorgi U, Basso U, Maruzzo M, Giannatempo P, Ponzano M, Giunta EF, Catalano F, Murianni V, Damassi A, Cremante M, Gandini A, Puglisi S, Llaja Obispo MA, Signori A, Banna GL. Fornarini G, et al. Among authors: rescigno p. Minerva Urol Nephrol. 2023 Jun;75(3):308-318. doi: 10.23736/S2724-6051.22.05135-7. Epub 2022 Dec 13. Minerva Urol Nephrol. 2023. PMID: 36511379 Free article. Clinical Trial.
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score.
Mazzaschi G, Lazzarin A, Santoni M, Trentini F, Giorgi U, Brighi N, Tommasi C, Puglisi S, Caffo O, Kinspergher S, Mennitto A, Cattrini C, Verzoni E, Rametta A, Stellato M, Malgeri A, Roviello G, Silini EM, Rescigno P, Rebuzzi SE, Fornarini G, Quaini F, Giudice GC, Banna GL, Buti S. Mazzaschi G, et al. Among authors: rescigno p. Front Biosci (Elite Ed). 2023 Jul 28;15(3):20. doi: 10.31083/j.fbe1503020. Front Biosci (Elite Ed). 2023. PMID: 37743233 Free article.
Prognostic models for patients with metastatic urothelial carcinoma: why use them?
Maffezzoli M, Campobasso D, Rebuzzi SE, Banna GL, Fornarini G, Signori A, Rescigno P, Buti S. Maffezzoli M, et al. Among authors: rescigno p. Minerva Urol Nephrol. 2023 Aug;75(4):419-421. doi: 10.23736/S2724-6051.23.05347-8. Epub 2023 May 11. Minerva Urol Nephrol. 2023. PMID: 37166132 Free article. No abstract available.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: rescigno p. Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12. Future Oncol. 2024. PMID: 38682738
130 results